Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort

Human Reproduction

Volumn 26, Issue 12, 2011, Pages 3456-3465

  Van Leeuwen, F E ^a   Klip, H ^a,b   Mooij, T M ^a   Van De Swaluw, A M G ^a,c   Lambalk, C B ^d   Kortman, M ^e   Laven, J S E ^f   Jansen, C A M ^g   Helmerhorst, F M ^h   Cohlen, B J ⁱ   Willemsen, W N P ^j   Smeenk, J M J ^k   Simons, A H M ^l   Van Der Veen, F ^m   Evers, J L H ⁿ   Van Dop, P A ^o   MacKlon, N S ^f,p   Burger, C W ^f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Center of Knowledge   (Netherlands)

^c Waterland Hospital   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Diaconessenhuis Voorburg ^*  (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ISALA HOSPITAL   (Netherlands)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^l UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o CATHARINA HOSPITAL   (Netherlands)

^p UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

fertility drugs; in vitro fertilization; infertility; ovarian malignancies; ovarian stimulation

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY TUMOR; STIMULATION;

EID: 81055146987     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der322     Document Type: Article

References (50)

1. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 1982; 61:261-263.
2. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18:S19-S32.
3. Breslow NE, Day NE. Comparisons among exposure groups. In: Breslow NE, Day NE (eds). Statistical Methods in Cancer Research, Volume II. Lyon: International Agency for Research on Cancer, 1987, 82-86.
4. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004;103:1194-1203.
5. Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ. Ovulation induction and cancer risk. Fertil Steril 2005;83:261-274.
6. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996;66:499-507.
7. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, Van de Pol A, Van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29:19-24.
8. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721.
9. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, Van Leeuwen FE. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003; 18:1544-1552.
10. de Boer EJ, Van Leeuwen FE, den Tonkelaar I, Jansen CA, Braat DD, Burger CW. [Methods and results of in-vitro fertilisation in the Netherlands in the years 1983-1994]. Ned Tijdschr Geneeskd 2004; 148:1448-1455.
11. Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1994; 11:408-421.
12. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77:324-327.
13. Dos Santos Silva I, Wark PA, McCormack VA, Mayer D, Overton C, Little V, Nieto J, Hardiman P, Davies M, MacLean AB. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer 2009;100:1824-1831.
14. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209-2213.
15. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972;27:751-768.
16. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? Br Med J 1989;299:309-311.
17. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, Parazzini F. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673-1675.
18. Glasier AF. Clomiphene citrate. Baillieres Clin Obstet Gynaecol 1990; 4:491-501.
19. Goldberg GL, Scheiner J, Friedman A, O'Hanlan KA, Davidson SA, Runowicz CD. Lymph node sampling in patients with epithelial ovarian carcinoma. Gynecol Oncol 1992;47:143-145.
20. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1204-1211.
21. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18:S33-S50.
22. Hermsen BB, Olivier RI, Verheijen RH, Van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96:1335-1342.
23. International Agency for Research on Cancer. Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2003;155:1-782.
24. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
25. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. Br Med J 2009; 338:b249.
26. Källén B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011;26:253-258.
27. Klip H, Burger CW, de Kraker J, Van Leeuwen FE. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Hum Reprod 2001;16:2451-2458.
28. Klip WAJ. Long-term health effects of subfertility treatment. Thesis. Vrije Universiteit, Amsterdam 2002.
29. Kremer JA, Bots RS, Cohlen B, Crooij M, Van Dop PA, Jansen CA, Land JA, Laven JS, Kastrop PM, Naaktgeboren N et al. [Ten years of results of in-vitro fertilisation in the Netherlands 1996-2005]. Ned Tijdschr Geneeskd 2008;152:146-152.
30. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003;13:23-27.
31. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038-1042.
32. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-1012.
33. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224.
34. Nijman HW, Burger CW, Baak JP, Schats R, Vermorken JB, Kenemans P. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992;28A:1971-1973.
35. Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, Surace M, Ricci E. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998;68:226-228.
36. Parazzini F, Pelucchi C, Negri E, Franceschi S, Talamini R, Montella M, La Vecchia C. Use of fertility drugs and risk of ovarian cancer. Hum Reprod 2001;16:1372-1375.
37. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.
38. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776.
39. Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004;160:1070-1078.
40. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 2009;91:1152-1158.
41. Sherman ME, Berman J, Birrer MJ, Cho KR, Ellenson LH, Gorstein F, Seidman JD. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol 2004;35:961-970.
42. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-1518.
43. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-18.
44. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486.
45. Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol 1990; 19:553-558.
46. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354: 1586-1590.
47. Verbruggen MB, Van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study. Int J Gynecol Pathol 2009;28:35-40.
48. Vlahos NF, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. Ann N Y Acad Sci 2010; 1205:214-219.
49. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-1203.
50. Wright VC, Chang J, Jeng G, Macaluso M. Assisted reproductive technology surveillance-United States, 2005. MMWR Surveill Summ 2008;57:1-23.